We concluded that patients with Notch pathway mutations often exhibit abnormalities in other oncogenic or tumor suppressor genes, reflecting a higher tumor mutational burden that may serve as a target for CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.